Key facts
- Oxitec’s last known valuation is $204.2M (Sep 2018).
- It has raised $49.2M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Innovate UK, Gates Foundation, University of Oxford, Wellcome Trust, H2O Venture Partners.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Oxitec
- ·The full record, as it builds
Funding rounds
No funding rounds for Oxitec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oxitec
Manufacturer of biological alternatives intended to control pests that transmit disease, destroy crops, and harm livestock. The company delivers targeted, non-toxic, scalable, safe, and environmentally sustainable options, enabling people to combat malaria and dengue.
- Sector
- Materials and Resources
- HQ
- Abingdon, United Kingdom
- Founded
- 2002
- Employees
- 158
- Website
- oxitec.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Oxitec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oxitec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oxitec in its N-PORT filings yet. We sweep new filings monthly.